Andrea Knezevic, MS

Research Biostatistician II

Andrea Knezevic, MS

Research Biostatistician II
Share
Share
Andrea Knezevic

Education

Georgia Institute of Technology

Current Research Interest

Andrea’s primary collaborations at MSKCC are with the Genitourinary Oncology Service. She is the lead statistician of clinical studies investigating novel therapeutic strategies in metastatic renal cell carcinoma and relapsed/refractory germ cell tumor. Her research collaborations involve the study of early biomarkers of relapsed disease, cancer genomics and cancer survivorship. Andrea’s biostatistical research interests include survival analysis in the presence of non-proportional hazards and methods for handling incomplete outcome data in competing risks analysis. Andrea serves as a Co-Chair of the Biostatistics Protocol Review Committee (BPRC) which reviews and approves all investigator-initiated research protocols at MSKCC. She serves as a statistical reviewer for Journal of Clinical Oncology, Journal of the National Cancer Institute (JNCI) and JNCI Cancer Spectrum.

Publications

  1. Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. J Clin Oncol. 2022 Jul 20;40(21):2333-2341. doi: 10.1200/JCO.21.01944. 
  2. Funt SA, Knezevic A, Wilson K, Bromberg M, Budnick A, O’Connor KL, McHugh DJ, Larsen E, Bajorin DF, Motzer RJ, Tonorezos ES, Patil S, Feldman DR. Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors. Cancer. 2023 Sep 16;. doi: 10.1002/cncr.34991. 
  3. Fitzgerald KN, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen DH, Carlo MI, Shah NJ, Voss MH, Feldman DR, Motzer RJ, Lee CH. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. Eur Urol. 2023 Mar;83(3):195-199. doi: 10.1016/j.eururo.2022.10.017.
  4. Ged Y, Chen YB, Knezevic A, Casuscelli J, Redzematovic A, DiNatale RG, Carlo MI, Lee CH, Feldman DR, Patil S, Hakimi AA, Russo P, Motzer RJ, Voss MH. Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. Clin Genitourin Cancer. 2019 Jun;17(3):e678-e688. doi: 10.1016/j.clgc.2019.03.018. 
  5. Carlo MI, Mukherjee S, Mandelker D, Vijai J, Kemel Y, Zhang L, Knezevic A, Patil S, Ceyhan-Birsoy O, Huang KC, Redzematovic A, Coskey DT, Stewart C, Pradhan N, Arnold AG, Hakimi AA, Chen YB, Coleman JA, Hyman DM, Ladanyi M, Cadoo KA, Walsh MF, Stadler ZK, Lee CH, Feldman DR, Voss MH, Robson M, Motzer RJ, Offit K. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncol. 2018 Sep 1;4(9):1228-1235. 

View a full listing of Andrea Knezevic’s journal articles.